Cocrystal Pharma, Inc.
COCP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.34 | 0.14 | 0.06 | 0.05 |
| FCF Yield | -10.00% | -14.22% | -20.34% | -15.38% |
| EV / EBITDA | -3.63 | -5.77 | -4.07 | -3.86 |
| Quality | ||||
| ROIC | -22.58% | -28.85% | -25.90% | -28.51% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.76 | 1.05 | 1.28 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 36.24% | 26.68% | 6.99% | 39.04% |
| Safety | ||||
| Net Debt / EBITDA | 2.94 | 1.49 | 2.28 | 2.49 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -3,668.57 | -2,908.80 | -4,152.38 |